Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.830
+0.250 (15.82%)
At close: Jun 22, 2026, 4:00 PM EDT
1.870
+0.040 (2.19%)
After-hours: Jun 22, 2026, 7:34 PM EDT
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
$19,597
Profits / Employee
-$3,585,676
Market Cap
221.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| LENZ Therapeutics | 152 |
| Tonix Pharmaceuticals Holding | 142 |
| MediWound | 121 |
| Alector | 103 |
| Immunic | 95 |
| Compugen | 75 |
| Korro Bio | 49 |
OTLK News
- 6 days ago - Outlook Therapeutics resubmits ONS-5010 biologics license application to FDA - TheFly
- 6 days ago - Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD - GlobeNewsWire
- 21 days ago - Outlook Therapeutics resubmits biologics license application to FDA - TheFly
- 21 days ago - Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) - GlobeNewsWire
- 21 days ago - Outlook Therapeutics Proxy statement: Proxy filing - Filings
- 21 days ago - Outlook Therapeutics Proxy statement: Proxy filing - Filings
- 25 days ago - Outlook Therapeutics announces pricing of $5M registered direct offering - TheFly
- 25 days ago - Outlook to sell 8.54M shares at 58.55c in registered direct offering - TheFly